Ear­ly sur­vival da­ta boost Zio­phar­m's 'con­trolled IL-12' im­munother­a­py for glioblas­toma

An un­con­ven­tion­al pair­ing of a gene ther­a­py and an oral drug that promis­es to at­tack re­cur­rent or pro­gres­sive glioblas­toma with con­trolled re­lease of IL-12 has turned up more promis­ing — if ear­ly — over­all sur­vival da­ta. On top of boost­ing its case as a monother­a­py, the da­ta can al­so bode well for a com­bi­na­tion with Re­gen­eron’s PD-1 in­hibitor, Lib­tayo.

Both the treat­ment and its de­vel­op­er, Zio­pharm On­col­o­gy, have come a long way. The stock price peaked in 2015 but cratered in 2016 fol­low­ing a pa­tient death in a Phase I.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER